2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
Primary objective is to investigate the feasibility of Hexvix® blue light URS. Secondary objectives are to determine the diagnostic value of Hexvix® blue light URS as compared to digital and fiberoptic white light URS, and to assess safety and…